WASHINGTON STATE MEDICAID WILL BEGIN NEW PRIOR AUTHORIZATION PROCEDURES FEB. 1
WASHINGTON STATE MEDICAID WILL BEGIN NEW PRIOR AUTHORIZATION PROCEDURES FEB. 1 for drugs from companies that have not agreed to provide supplemental rebates. Washington Medicaid will not reimburse product lines of those companies after January unless authorization is obtained by providers before claims are submitted for payment. Acting on instruction from the state legislature, the Medicaid agency designed its supplemental rebate program to produce savings of 5% off of Medical Assistance Administration's estimated drug ingredient costs for 1993-95. The two-year funding for MAA was cut by $10.6 mil.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth